Biopharmaceuticals

#Bioengineering #Biopharmaceuticals #Podcast #RNA #Therapeutics

Antibody engineering: why collaboration matters – podcast

The latest DDW Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why… Read More

#News

#Biologics #Biopharmaceuticals #Drug delivery #Drug development #Events #Process analytical technology

Agilent completes the InfinityLab Bio LC portfolio

Agilent Technologies has launched three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release has been described by Agilent as central to its portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that integrate with Agilent OpenLab and MassHunter software, and… Read More

#News

#Biopharmaceuticals #Drug delivery #Mass spectrometry / NMR

MOBILion System launches high-resolution Ion Mobility instrument

MOBILion is advancing separation science with the commercialisation of High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS) based on Structures for Lossless Ion Manipulation (SLIM). This product addresses characterisation challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides resolution and reproducibility, faster, simpler method development, and greater instrument uptime. This… Read More

#News

#Biopharmaceuticals #Life sciences #Pharma #STEM

Lab To Leadership: inspiring leaders in STEM

Aly King-Smith is Director of Clearworks, based at the historic Caswell Science Park in Northamptonshire. King-Smith speaks with DDW’s Megan Thomas about Clearworks’ Lab To Leadership initiative, established to inspire leaders in STEM. MT: Could you provide a general overview of the course and the company behind it? AKS: Lab… Read More

#Exclusive Content #News

#AstraZeneca #Biopharmaceuticals #Covid-19 #Immunology / Virology & Vaccines

AstraZeneca vaccine is 92% effective against Delta variant

New data from Public Health England (PHE) demonstrated AstraZeneca’s Covid-19 vaccine offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian’ variant). Real world data from PHE, published as a pre-print, demonstrated two doses of AstraZeneca are 92% effective against hospitalisation due to the Delta variant and… Read More

#Covid-19 #News #Trending News

#Biopharmaceuticals #Data #Laboratory data

Laboratory data partnership

IDBS, innovator in Biopharmaceutical Lifecycle Management (BPLM), and Scitara, expert in laboratory IoT, have partnered to create a solution that will extend IDBS Polar BPLM’s laboratory data connectivity and instrument integration capabilities. This solution boosts the Polar workflow capabilities by addressing the challenge of sharing and digitalising laboratory data across… Read More

#News

#Biopharmaceuticals #Pharma

Sanofi’s €3 million environmental pledge

Biopharmaceutical innovator Sanofi has launched a €3 million Planet Mobilisation fund to support employee ideas and projects that will further contribute to a healthier environment. In 2021, three Sanofi teams will have their projects implemented and funded. For several years, Sanofi has been implementing a global environmental roadmap, Planet Mobilisation,… Read More

#News

#3D modelling #Biopharmaceuticals #Biotechnology #Drug screening #Drug targets

Optibrium and BioPharmics computational drug design partnership

The first outcome of the Optibrium and BioPharmics collaboration will be a new module for StarDrop, Optibrium’s small molecule design, optimisation and analysis software,. The new Surflex eSim 3D module, planned for the third quarter of 2021, will leverage BioPharmics’ three-dimensional (3D) ligand-based design approaches, offering exceptional virtual screening and… Read More

#News

#Biopharmaceuticals #Biotechnology #Drug development #Novel therapeutics

PerkinElmer acquires Nexcelom Bioscience

PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for US$260 million. The transaction is expected to close during the second quarter of 2021. Nexcelom provides automated cell counting instruments and aids in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines. Its expected 2021… Read More

#News

#Biopharmaceuticals #Drug development #Life sciences

Awakn Life Sciences and Evotec start chemical entity programme

Awakn Life Sciences, a biotechnology company focused on addiction, has initiated a new chemical entity (NCE) development programme to strengthen its pipeline for the treatment of a broad range of addictions. The company has also announced the appointment of Evotec as its NCE research partner and the selection of… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Drug delivery #Drug development #Drug discovery

Putting the power into drug design: the important role of AI

Valence’s co-founder and CEO, Daniel Cohen, spoke to Lu Rahman about the company’s plan to empower drug discovery scientists with AI-enabled drug design LR:  Outline of the company and its main initiatives DC: Valence is an interdisciplinary team of scientists and engineers out of Mila, the world’s largest deep learning… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biopharmaceuticals #Biotechnology #Life sciences

New initiative focusses on Lab To Leadership in drug discovery

Clearworks Coaching is offering a Lab To Leadership initiative that aims to assist leadership development, helping scientists reach their leadership potential early in their career. Clearworks Coaching has been developing UK senior leaders since 2005 and specialises in STEM, biotech and pharma. The organisation has recognised that the gap between… Read More

#News

#Biopharmaceuticals #Data #Drug development #Life sciences

Price control could cut medicine development by 88% in California

Researchers from Biocom California and the California Life Sciences Association (CLSA) have released data analysing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline. The analysis shows that implementing foreign reference… Read More

#News

#Biopharmaceuticals #Drug development #Drug discovery #Oncology

LDC and Cumulus Oncology announce collaboration

The Lead Discovery Centre (LDC) and Cumulus Oncology are collaborating to enable the two organisations to accelerate the discovery and development of novel oncology therapies. LDC contributes drug discovery expertise and a team of scientists with the ability to develop assets modulating a range of oncology targets derived from its… Read More

#News

#Biopharmaceuticals #Biotechnology #Drug discovery #Market reporting #Pharmatech

Pharma report predicts growth of contract services by 2025

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive Covid-19 legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in… Read More

#Market Reports #News